Teri A. Manolio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teri A. Manolio has a total of 482 co-authors. Here are the top co-authors by number of shared publications:
Dan M. Roden
Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
11 shared publicationsEric D. Green
National Human Genome Research Institute National Institutes of Health Bethesda Maryland USA
11 shared publicationsMarc S. Williams
Department of Genomic Health, Geisinger, Danville, PA 17822, USA
11 shared publicationsRex L. Chisholm
Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
11 shared publicationsGail P. Jarvik
Departments of Medicine (Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA 98195, USA
10 shared publicationsGeoffrey S. Ginsburg
All of Us Research Program, National Institutes of Health, Bethesda, MD 20892, USA
10 shared publications
Latest Publications
- 15 January 2026
- Published by Springer Nature in Nature
- Vol. 649 (8098) , 830-831
Nationwide genetic screening proves effective at catching disease risk early
- 15 January 2026
- Published by Springer Nature in Nature
- Vol. 649 (8098) , 830-831
Nationwide genetic screening proves effective at catching disease risk early
- 4 December 2025
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 112 (12) , 2822-2825
Genomic medicine year in review: 2025
- 4 December 2025
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 112 (12) , 2822-2825
Genomic medicine year in review: 2025
- Open Access
- 23 July 2025
- Published by Wiley in Learning Health Systems
- Vol. 9 (4)
Advancing the science of genomic learning healthcare systems
Introduction: Identifying key characteristics of exemplar genomic learning healthcare systems (gLHS) and knowledge gaps that can be explored by collaboration among them is likely to accelerate the sharing of best practices and generation of evidence that informs the use of genomics in clinical care. Methods: Deliberations of an expert group convened by the National Human Genome Research Institute (NHGRI) supplemented by relevant literature. Results: Recent advances in genomic data standardization, automated clinical decision support, increased interoperability, and improved genomic technologies have enabled the development of several robust gLHS . They remain concentrated in major academic centers, however, and operate largely independently. Sharing their methods and tools would increase access to these innovations and advance the field. Several gLHS have expressed willingness to collaborate in a coalition designed to gather, evaluate, and disseminate best practices and development needs. Such a coalition has recently been formed under the leadership of NHGRI. Conclusion: Increased collaboration, interoperability, and sharing of genomic information and strategies across gLHS can help define, refine, and disseminate best practices. Such cooperation can improve genomic variant curation and interpretation, diagnostic accuracy, evidence generation, and ultimately patient care through seamless integration of research as an integral component of good clinical care.
- 23 July 2025
- Published by Wiley in Learning Health Systems
- Vol. 9 (4)
Open AccessAdvancing the science of genomic learning healthcare systems
Introduction: Identifying key characteristics of exemplar genomic learning healthcare systems (gLHS) and knowledge gaps that can be explored by collaboration among them is likely to accelerate the sharing of best practices and generation of evidence that informs the use of genomics in clinical care. Methods: Deliberations of an expert group convened by the National Human Genome Research Institute (NHGRI) supplemented by relevant literature. Results: Recent advances in genomic data standardization, automated clinical decision support, increased interoperability, and improved genomic technologies have enabled the development of several robust gLHS . They remain concentrated in major academic centers, however, and operate largely independently. Sharing their methods and tools would increase access to these innovations and advance the field. Several gLHS have expressed willingness to collaborate in a coalition designed to gather, evaluate, and disseminate best practices and development needs. Such a coalition has recently been formed under the leadership of NHGRI. Conclusion: Increased collaboration, interoperability, and sharing of genomic information and strategies across gLHS can help define, refine, and disseminate best practices. Such cooperation can improve genomic variant curation and interpretation, diagnostic accuracy, evidence generation, and ultimately patient care through seamless integration of research as an integral component of good clinical care.
- 5 December 2024
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 111 (12) , 2585-2588
Genomic medicine year in review: 2024
- 5 December 2024
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 111 (12) , 2585-2588
Genomic medicine year in review: 2024
- Open Access
- 29 August 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (9) , e70017
Patterns of pharmacogenetic variation in nine biogeographic groups
Frequencies of pharmacogenetic (PGx) variants are known to differ substantially across populations but much of the available PGx literature focuses on one or a few population groups, often defined in nonstandardized ways, or on a specific gene or variant. Guidelines produced by the Clinical Pharmacogenetic Implementation Consortium (CPIC) provide consistent methods of literature extraction, curation, and reporting, including comprehensive curation of allele frequency data across nine defined “biogeographic groups” from the PGx literature. We extracted data from 23 CPIC guidelines encompassing 19 genes to compare the sizes of the populations from each group and allele frequencies of altered function alleles across groups. The European group was the largest in the curated literature for 16 of the 19 genes, while the American and Oceanian groups were the smallest. Nearly 200 alleles were detected in nonreference groups that were not reported in the largest (reference) group. The genes CYP2B6 and CYP2C9 were more likely to have higher frequencies of altered function alleles in nonreference groups compared to the reference group, while the genes CYP4F2, DPYD, SLCO1B1, and UGT1A1 were less likely to have higher frequencies in nonreference groups. PGx allele frequencies and function differ substantially across nine biogeographic groups, all but two of which are underrepresented in available PGx data. Awareness of these differences and increased efforts to characterize the breadth of global PGx variation are needed to ensure that implementation of PGx‐guided drug selection does not further widen existing health disparities among populations currently underrepresented in PGx data.
- 29 August 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (9) , e70017
Open AccessPatterns of pharmacogenetic variation in nine biogeographic groups
Frequencies of pharmacogenetic (PGx) variants are known to differ substantially across populations but much of the available PGx literature focuses on one or a few population groups, often defined in nonstandardized ways, or on a specific gene or variant. Guidelines produced by the Clinical Pharmacogenetic Implementation Consortium (CPIC) provide consistent methods of literature extraction, curation, and reporting, including comprehensive curation of allele frequency data across nine defined “biogeographic groups” from the PGx literature. We extracted data from 23 CPIC guidelines encompassing 19 genes to compare the sizes of the populations from each group and allele frequencies of altered function alleles across groups. The European group was the largest in the curated literature for 16 of the 19 genes, while the American and Oceanian groups were the smallest. Nearly 200 alleles were detected in nonreference groups that were not reported in the largest (reference) group. The genes CYP2B6 and CYP2C9 were more likely to have higher frequencies of altered function alleles in nonreference groups compared to the reference group, while the genes CYP4F2, DPYD, SLCO1B1, and UGT1A1 were less likely to have higher frequencies in nonreference groups. PGx allele frequencies and function differ substantially across nine biogeographic groups, all but two of which are underrepresented in available PGx data. Awareness of these differences and increased efforts to characterize the breadth of global PGx variation are needed to ensure that implementation of PGx‐guided drug selection does not further widen existing health disparities among populations currently underrepresented in PGx data.
- Top Cited PapersOpen Access
- 19 February 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (2) , 480-487
Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations
Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can be implemented in the clinic, including reduced predictive performance of PRSs in diverse populations, and the interpretation and communication of genetic results to both providers and patients. To address these challenges, the National Human Genome Research Institute-funded Electronic Medical Records and Genomics (eMERGE) Network has developed a framework and pipeline for return of a PRS-based genome-informed risk assessment to 25,000 diverse adults and children as part of a clinical study. From an initial list of 23 conditions, ten were selected for implementation based on PRS performance, medical actionability and potential clinical utility, including cardiometabolic diseases and cancer. Standardized metrics were considered in the selection process, with additional consideration given to strength of evidence in African and Hispanic populations. We then developed a pipeline for clinical PRS implementation (score transfer to a clinical laboratory, validation and verification of score performance), and used genetic ancestry to calibrate PRS mean and variance, utilizing genetically diverse data from 13,475 participants of the All of Us Research Program cohort to train and test model parameters. Finally, we created a framework for regulatory compliance and developed a PRS clinical report for return to providers and for inclusion in an additional genome-informed risk assessment. The initial experience from eMERGE can inform the approach needed to implement PRS-based testing in diverse clinical settings.
- 19 February 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (2) , 480-487
Top Cited PapersOpen AccessSelection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations
Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can be implemented in the clinic, including reduced predictive performance of PRSs in diverse populations, and the interpretation and communication of genetic results to both providers and patients. To address these challenges, the National Human Genome Research Institute-funded Electronic Medical Records and Genomics (eMERGE) Network has developed a framework and pipeline for return of a PRS-based genome-informed risk assessment to 25,000 diverse adults and children as part of a clinical study. From an initial list of 23 conditions, ten were selected for implementation based on PRS performance, medical actionability and potential clinical utility, including cardiometabolic diseases and cancer. Standardized metrics were considered in the selection process, with additional consideration given to strength of evidence in African and Hispanic populations. We then developed a pipeline for clinical PRS implementation (score transfer to a clinical laboratory, validation and verification of score performance), and used genetic ancestry to calibrate PRS mean and variance, utilizing genetically diverse data from 13,475 participants of the All of Us Research Program cohort to train and test model parameters. Finally, we created a framework for regulatory compliance and developed a PRS clinical report for return to providers and for inclusion in an additional genome-informed risk assessment. The initial experience from eMERGE can inform the approach needed to implement PRS-based testing in diverse clinical settings.
- 7 December 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (12) , 1992-1995
Genomic medicine year in review: 2023
- 7 December 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (12) , 1992-1995
Genomic medicine year in review: 2023
- 1 September 2023
- Published by Wiley in Journal of Genetic Counseling
- Vol. 33 (4) , 733-744
Survey of the training needs of genetic assistants supports the creation of genetic assistant training programs
Despite the increasing numbers of genetic assistants (GAs) in the genomics workforce, their training needs and how to best prepare GAs for their role have not been well defined. We sought to identify the current educational status of GAs, opinions on their training needs, and attitudes about GA training programs (GATPs). Survey links were emailed to NSGC members, 17 state genetic counseling (GC) professional organizations, and genomic medicine researchers. Respondents (n = 411) included GCs (n = 231) and GAs (n = 136). Like other studies, we found that the GA position is filled by a range of education levels and career aspirations. Most respondents supported the creation of GATPs, with 63% endorsing that GATPs would be helpful and half endorsing a short-term (3 months or less) program. Most believed GATPs should focus on general knowledge, with almost all practical skills learned on-the-job. If more GATPs are created, our survey provides evidence that graduates would be hired. Indeed, of those whose work setting required a bachelor's degree, the number of respondents who favored keeping that requirement was similar to the number who favored hiring a GA without a degree if they attended a GATP. However, there were concerns about GATPs. Many (44%) believed creating GATPs could discourage candidates from becoming GAs. We observed that there are two types of GAs: entry-level and bachelor's-level, with the entry-level being those who do not have and are not working to obtain a bachelor's degree and the bachelor's-level being those who do/are. GATPs could focus on the education of entry-level GAs, while gaps in the knowledge base of bachelor's-level GAs could be addressed by augmenting bachelor's curriculum or providing additional training after hire. Further research on the training needs of GAs and hiring practices of institutions will be vital to understanding their training needs and designing and implementing effective GATPs.
- 1 September 2023
- Published by Wiley in Journal of Genetic Counseling
- Vol. 33 (4) , 733-744
Survey of the training needs of genetic assistants supports the creation of genetic assistant training programs
Despite the increasing numbers of genetic assistants (GAs) in the genomics workforce, their training needs and how to best prepare GAs for their role have not been well defined. We sought to identify the current educational status of GAs, opinions on their training needs, and attitudes about GA training programs (GATPs). Survey links were emailed to NSGC members, 17 state genetic counseling (GC) professional organizations, and genomic medicine researchers. Respondents (n = 411) included GCs (n = 231) and GAs (n = 136). Like other studies, we found that the GA position is filled by a range of education levels and career aspirations. Most respondents supported the creation of GATPs, with 63% endorsing that GATPs would be helpful and half endorsing a short-term (3 months or less) program. Most believed GATPs should focus on general knowledge, with almost all practical skills learned on-the-job. If more GATPs are created, our survey provides evidence that graduates would be hired. Indeed, of those whose work setting required a bachelor's degree, the number of respondents who favored keeping that requirement was similar to the number who favored hiring a GA without a degree if they attended a GATP. However, there were concerns about GATPs. Many (44%) believed creating GATPs could discourage candidates from becoming GAs. We observed that there are two types of GAs: entry-level and bachelor's-level, with the entry-level being those who do not have and are not working to obtain a bachelor's degree and the bachelor's-level being those who do/are. GATPs could focus on the education of entry-level GAs, while gaps in the knowledge base of bachelor's-level GAs could be addressed by augmenting bachelor's curriculum or providing additional training after hire. Further research on the training needs of GAs and hiring practices of institutions will be vital to understanding their training needs and designing and implementing effective GATPs.
- Top Cited PapersOpen Access
- 1 June 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (6) , 903-912
eXclusionarY: 10 years later, where are the sex chromosomes in GWASs?
- 1 June 2023
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 110 (6) , 903-912
Top Cited PapersOpen AccesseXclusionarY: 10 years later, where are the sex chromosomes in GWASs?
- 1 April 2023
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 16 (2) , e003816
Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results
Background: The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network. Methods: Adult participants (n=18 544) at 7 sites were enrolled in a prospective cohort study to assess the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . FH variant prevalence and penetrance (defined as low-density lipoprotein cholesterol >155 mg/dL) were estimated after excluding participants enrolled on the basis of hypercholesterolemia. Multivariable logistic regression was used to estimate the odds of CHD compared to age- and sex-matched controls without FH-associated variants. Process (eg, referral to a specialist or ordering new tests), intermediate (eg, new diagnosis of FH), and clinical (eg, treatment modification) outcomes within 1 year after return of results were ascertained by electronic health record review. Results: The prevalence of FH-associated pathogenic variants was 1 in 188 (69 of 13,019 unselected participants). Penetrance was 87.5%. The presence of an FH variant was associated with CHD (odds ratio, 3.02 [2.00–4.53]) and premature CHD (odds ratio, 3.68 [2.34–5.78]). At least 1 outcome occurred in 92% of participants; 44% received a new diagnosis of FH and 26% had treatment modified following return of results. Conclusions: In a multisite cohort of electronic health record–linked biobanks, monogenic FH was prevalent, penetrant, and associated with presence of CHD. Nearly half of participants with an FH-associated variant received a new diagnosis of FH and a quarter had treatment modified after return of results. These results highlight the potential utility of sequencing electronic health record–linked biobanks to detect FH.
- 1 April 2023
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 16 (2) , e003816
Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results
Background: The implications of secondary findings detected in large-scale sequencing projects remain uncertain. We assessed prevalence and penetrance of pathogenic familial hypercholesterolemia (FH) variants, their association with coronary heart disease (CHD), and 1-year outcomes following return of results in phase III of the electronic medical records and genomics network. Methods: Adult participants (n=18 544) at 7 sites were enrolled in a prospective cohort study to assess the clinical impact of returning results from targeted sequencing of 68 actionable genes, including LDLR , APOB , and PCSK9 . FH variant prevalence and penetrance (defined as low-density lipoprotein cholesterol >155 mg/dL) were estimated after excluding participants enrolled on the basis of hypercholesterolemia. Multivariable logistic regression was used to estimate the odds of CHD compared to age- and sex-matched controls without FH-associated variants. Process (eg, referral to a specialist or ordering new tests), intermediate (eg, new diagnosis of FH), and clinical (eg, treatment modification) outcomes within 1 year after return of results were ascertained by electronic health record review. Results: The prevalence of FH-associated pathogenic variants was 1 in 188 (69 of 13,019 unselected participants). Penetrance was 87.5%. The presence of an FH variant was associated with CHD (odds ratio, 3.02 [2.00–4.53]) and premature CHD (odds ratio, 3.68 [2.34–5.78]). At least 1 outcome occurred in 92% of participants; 44% received a new diagnosis of FH and 26% had treatment modified following return of results. Conclusions: In a multisite cohort of electronic health record–linked biobanks, monogenic FH was prevalent, penetrant, and associated with presence of CHD. Nearly half of participants with an FH-associated variant received a new diagnosis of FH and a quarter had treatment modified after return of results. These results highlight the potential utility of sequencing electronic health record–linked biobanks to detect FH.